GSK’s RSV Vaccine Approved in Europe

Why It Matters

The approval fills a critical gap in adult RSV prevention, potentially lowering hospitalisations and boosting GSK’s vaccine revenues across a larger market.

Key Takeaways

• Arexvy now approved for all EU adults 18+.
• RSV causes ~158k EU adult hospitalizations annually.
• Expanded indication could boost GSK vaccine revenues.
• GSK also pursuing US, Japan approvals for Arexvy.
• Trelegy Ellipta gains Chinese asthma indication.

Pulse Analysis

Respiratory syncytial virus, long associated with severe illness in infants, has emerged as a leading cause of adult morbidity across Europe. Recent epidemiological studies estimate roughly 158,000 hospital admissions each year among EU adults, with higher fatality rates in patients with chronic lung disease. Historically, vaccine strategies focused on seniors, leaving a sizable gap for younger, at‑risk populations. The growing clinical and economic burden has prompted regulators and manufacturers to prioritize broader immunisation programmes, setting the stage for an expanded adult vaccine rollout.

GSK’s Arexvy employs an adjuvanted recombinant platform that presents stabilized RSV F‑protein antigens, eliciting robust neutralising antibodies across age groups. The European Commission’s January 26 decision extends the product’s label from seniors and high‑risk 50‑to‑59‑year‑olds to all adults 18 years and older, marking the first pan‑adult RSV indication in the EU. Analysts project that the broadened market could add several hundred million euros to GSK’s vaccine pipeline, especially as national health services incorporate the shot into routine adult immunisation schedules. The approval also smooths the path for pending submissions in the United States and Japan.

The RSV clearance arrives alongside GSK’s recent respiratory triumph in China, where Trelegy Ellipta secured a dual asthma‑COPD indication, reinforcing the company’s triple‑therapy leadership. Together, these launches illustrate GSK’s strategic push to dominate the global respiratory market, leveraging a diversified pipeline that spans vaccines, inhaled medicines, and biologics. Competitors such as Pfizer and Moderna are accelerating their own RSV programmes, intensifying head‑to‑head trials and pricing debates. For European health systems, the broader Arexvy coverage promises reduced hospital strain and a new revenue stream for manufacturers, while patients gain a vital preventive tool.